What is the BPC-157 dosage for tendonitis?

How Tendonitis Dosing Differs From Other BPC-157 Uses

Tendon healing is one of the most common reasons patients seek BPC-157. Tendon tissue is poorly vascularized and heals slowly with conventional care (physical therapy, eccentric loading, NSAIDs) — which is precisely why BPC-157's angiogenic and fibroblast-stimulating properties have generated so much clinical interest. Tendonitis protocols tend to be longer and more aggressive than gut-focused protocols, because tendon remodeling takes weeks regardless of how strong the pro-healing signal is.

Typical Dosing Range

Across peptide therapy practice and published rodent-to-human scaling, the most commonly used range for tendonitis is:

• Daily dose: 250–500 mcg subcutaneously
• Frequency: Once daily, or split as 125–250 mcg morning and evening
• Cycle length: 4–8 weeks continuous, with a 2–4 week off-cycle
• Weight-based scaling: Some practitioners calibrate around 2–4 mcg/kg/day, though the evidence base for strict weight-based dosing in humans is limited

Systemic vs Local (Site-Rotation) Injection

A central question in tendonitis protocols is whether to inject systemically (abdomen, thigh) or locally (subcutaneously around the affected tendon). The published preclinical literature used both approaches with beneficial effects. In clinical practice:

• Systemic subcutaneous: Simple, well-tolerated, broadly effective. The default for most practitioners.
• Localized subcutaneous rotation: Injecting near the affected tendon (e.g., around the Achilles or lateral epicondyle) may produce higher local concentrations. This is common practice in sports medicine settings. Intra-tendinous or intra-articular injection is not typically recommended — subcutaneous near the tendon is the sweet spot for safety.

What a Realistic 8-Week Tendonitis Protocol Looks Like

A representative, clinician-guided protocol for moderate tendonitis might look like:

• Weeks 1–4: 250 mcg twice daily subcutaneous, site-rotated near the affected tendon and in the abdomen
• Weeks 5–8: 500 mcg once daily subcutaneous
• Week 9+: 2-week washout; reassess; consider second cycle if progress stalled

Combining With Mechanical Therapy

BPC-157 is a pro-healing signal — not a substitute for loading the tissue. Tendon remodeling responds to controlled mechanical stress. Combining BPC-157 with eccentric loading, isometric holds, and progressive return-to-sport work produces better outcomes than either alone. Many experienced clinicians insist that patients continue physical therapy during a BPC-157 cycle and credit the mechanical input, not the peptide alone, for durable recovery.

Injection Technique

BPC-157 is reconstituted with bacteriostatic water and administered with an insulin-gauge needle (typically 29–31G, 5/16 to 1/2 inch). Subcutaneous technique: pinch the skin, insert at 45–90 degrees, aspirate briefly, and inject slowly. Rotate sites daily to avoid local tissue irritation.

Important Cautions

• BPC-157 is a research peptide — it is not FDA-approved. Access in the United States is through 503A/503B compounding pharmacies working with licensed providers.
• Dosing protocols in practice are extrapolated from preclinical data and clinical experience; formal human dose-ranging trials for tendonitis have not been conducted.
• If systemic side effects emerge (GI upset, blood pressure changes), pause the cycle and consult your provider.
• Do not self-compound or attempt to mix BPC-157 with TB-500 in the same syringe without explicit pharmacy guidance — incompatibility and sterility issues arise.

This information is educational and not medical advice. Work with a qualified peptide therapy provider to determine protocols appropriate for your injury, goals, and medical history. For a broader overview of BPC-157 including clinical evidence and safety, see our main BPC-157 guide.